AbstractÐSeveral RGD peptidomimetics have been prepared, in a convergent way, from the common ortho-aminotyrosine template (O-substituted with an anchorage-arm or a methyl group, and aN-substituted with a¯uorine tag for XPS analysis), and various o-aminoacid derivatives. The most¯exible compounds have shown a biological activity similar to that of the peptide reference (RGDS) in the platelet aggregation test. The compound 16a could be ®tted (by modelisation) with DMP 728 and c(RGDfV), two cyclic peptides that are good ligands of integrins. The compound 16b has been covalently ®xed on the surface of a poly(ethylene terephthalate) membrane used as support for mammalian cell cultivation. #
Introduction
The use of synthetic polymers in medical engineering and biotechnological applications has increased considerably in recent years. 1, 2 For instance, polymer membranes are developed as supports for in vitro cultivations of mammalian cells used as models of biological barriers to investigate transport of nutrients or pharmacological agents. 3±5 Our interest in this ®eld led us to perform surface modi®cations of the supports in view to improve the cellular adhesion and growth. 6 A ®rst approach consisted in the introduction of functional motifs susceptible to increase the surface hydrophilicity and charge. 7±13 The chemically modi®ed surfaces were further biocompatibilized by the covalent coupling of extracellular matrix (ECM) proteins. 6, 14 Our current purpose is to replace proteins by stable synthetic biological signals that would similarly promote cell anchorage. Accordingly, our active biocompatibilization strategy of polymeric substrates relies on the covalent ®xation of small molecules acting as integrin ligands onto the material surface.
Integrins 15 are heterodimeric transmembrane glycoproteins involved in cell±cell and cell±matrix interactions; 16 these cell surface receptors interact with the cytoskeleton and play a crucial role in the signal transduction processes. 17 Most of integrins bind to adhesive proteins displaying the Arg-Gly-Asp (RGD) sequence. 18 Platelets aggregation is mediated by the a IIb b 3 integrin, which natural ligand is the blood protein ®brinogen. 19 The related integrin a v b 3 of endothelial cells has been recognized as an important mediator of cellular adhesion and migration in the angiogenesis process; 20 in this case, the natural ligand is the ECM protein vitronectin. A lot of¯exible linear peptides containing the RGD sequence bind to integrins, but non speci®cally. 21 On the other hand, cyclic RGD peptides appear more selective towards either a IIb b 3 or a v b 3 integrins. 22 Over the last 10 years, peptidomimetics 23±25 of the RGD sequence have been developed as potential drugs, mainly in the ®eld of orally available anticoagulants (a IIb b 3 antagonists) for the treatment of thromboembolic diseases. 26 Very recently, the search of a v b 3 antagonists has emerged in order to treat cancers 27 and other disorders in which neovascularization plays a critical role. 28 We planned to functionalize our cell culture substrates with RGD peptidomimetics. In the previous literature, the grafting of RGD peptides was reported to signi®cantly improve the cellular adhesion on various polymeric supports. 29±31 However the eect of nonpeptide mimics was never considered, though such synthetic signals should be more stable under biological uids, storage and sterilization conditions.
In this paper we report the preparation of several RGD peptidomimetics based on the ortho-amino-tyrosine template, and their evaluation in the classical platelet aggregation test. One molecule (16b) equipped with an anchorage-arm has been covalently ®xed on a poly (ethylene terephthalate) (PET) microporous membrane used as cell cultivation support.
Results and Discussion

Synthesis
Several series of RGD peptidomimetics based on various rigid scaolds 32, 33 have been proposed as antiplatelet agents; for instance, molecules were constructed from benzodiazepine, 34 isoquinolone, 35 isoxazoline, 36 pyrazolopiperazinone, 37 or 3-(hydroxymethyl) benzamide 38 moieties. The situation appears totally dierent in the case of RGD mimics designed to promote adhesion phenomena; to our knowledge, only four types of molecules have been very recently disclosed, based on phydroxybenzamide, 27 piperazine, 39 carbohydrate, 40 or benzodiazepine 27, 41 templates.
When starting this work, without reliable guide in hand, we decided to examine relatively¯exible structures derived from (l)-tyrosine. The utilization of this template has been well exempli®ed by the Merck's scientists; 42,43 one compound (Aggrastat 2 , MK-383) is in phase III clinical trials. 44 The advantages of the tyrosine template and the designed structural features of our RGD peptidomimetics are summarized in the Figure 1 : (a) the aromatic template is commercially available and already equipped with the ®rst arm mimicking the d (Asp) residue; (b) the a-amino function, that has to be masked with a lipophilic group, 43 can be advantageously used for the ®xation of a¯uorine tag in view of the X-ray photoelectron spectroscopic (XPS) analysis of the ®nal polymer substrates; 45, 46 (c) the aromatic hydroxyl function can be used to anchor a second arm needed for immobilizing the molecule onto polymer substrates; (d) nitration of the aromatic ring, followed by reduction, oers the anchorage point of the third arm mimicking the R (Arg) residue; the distance separating the acidic and basic residues of the pharmacophore should be within 10±20 A Ê . 27, 43, 47 The N-tri¯uoroacetyl group was initially chosen as uorine tag for the XPS analysis of the surface modi®ed polymer membranes. Therefore, in our synthetic plan, we have avoided using protective groups removable under basic conditions that could cleave our spectroscopic label; accordingly, we played exclusively with the classical tertio-butyl ( t Bu), tertio-butoxycarbonyl (Boc), and benzyloxycarbonyl (Cbz) groups.
(l)-Tyrosine tertio-butylester 1 was reacted with neat tri¯uoroacetic anhydride to give N-tri¯uoroacetyl-(l)-tyrosine tertio-butylester. This intermediate was directly treated with a solution of nitric acid in acetic acid at low temperature to furnish the mono-nitration product 2 isolated by column-chromatography (Scheme 1).
For chemoselectivity reasons, the O-alkylation of the phenol ring has to be performed before the reduction of the nitro group, and the subsequent functionalization of the resulting aniline. This Williamson reaction, planned to introduce the anchorage-arm for immobilization onto polymer membranes, was ®rst examined with methyliodide. Thus, 2 was reacted with methyliodide, in re¯uxing acetonitrile, in the presence of powdered potassium carbonate and a crown ether as catalyst. The product 3a, contaminated with a small amount of Nmethylation product of the tri¯uoroacetamide residue, was puri®ed by preparative medium pressure liquid chromatography (MPLC) in 72% yield. The N-protected anchorage-arm, N-(Boc)-3-bromopropylamine, could be similarly coupled to 2, giving 3b in 78% yield after puri®cation (Scheme 1).
The aromatic ring functionalization with various arms mimicking the basic residue of Arg was systematically investigated, using the precursor 3a in which the anchorage-arm is replaced with a simple methyl group. Reduction of 3a by catalytic hydrogenation over platinium oxide furnished the key-intermediate aniline 4a which was directly used without puri®cation. The reactivity of this aniline in the peptide coupling reaction was examined, under various experimental conditions, using N-(Cbz)-5-aminovaleric acid as partner. Low yields of the anilide 5a were obtained when the acid was activated in situ with diisopropylcarbodiimide/dimethylaminopyridine, dicyclohexyl-carbodiimide/N-hydroxysuccinimide, or O-benzotriazol-1-yl-N,N,N H ,N H -tetramethyluroniumhexauorophosphate (HBTU). The best results were obtained when preforming the acid chloride with thionyl chloride or 1-chloro-N,N, 2-trimethylpropenylamine; 48 reaction of N-(Cbz)-5-aminovaleryl chloride with 4a and triethylamine in dichloromethane at room temperature gave 45% yield of the coupling product 5a after puri®cation by column-chromatography. This strategy was thus selected for the coupling of N-(Cbz)-6-aminocaproic acid, N-(Cbz)-isonipecotic acid and N-(Cbz)-nipecotic acid. Reaction of the corresponding preformed acid chlorides with 4a led, respectively, to the anilides 6a, 7a, and 8a in 35±55% yields (Scheme 1).
Hydrogenolysis of the Cbz protective group of 5a gave the free amine 11a (tBu ester) which was submitted to various guanidylation conditions. Unfortunately, all attempts to react 11a with unprotected guanidylation reagents (i.e. aminoiminomethane sulfonic acid 49 and 1H-pyrazole-1-carboxamidine) 50 and with the protected reagent 17, N,N H -ditertio-butoxycarbonyl-3,5-dimethylpyrazole-1-carboxamidine, 51 failed. Therefore, we considered a more convergent route towards 9a (or 15a) and 10a (or 16a), using N-guanidyl-aminoacid derivatives as partners in the peptide coupling with the aniline 4a. The required acid chlorides 20 were obtained according to the Scheme 2.
5-Aminovaleric acid (a, n=4) and 6-aminocaproic acid (b, n=5) were esteri®ed with benzyl alcohol under standard conditions (18a,b), then reacted with N,N H -ditertiobutoxycarbonyl-3,5-dimethylpyrazole-1-carboxamidine 17 51 and triethylamine in dichloromethane. After preparative MPLC, compounds 19a,b were quantitatively obtained. Cleavage of the benzyl ester by hydrogenolysis, followed by reaction with thionyl chloride gave the acid chlorides 20a,b, which were not puri®ed (Scheme 2). Reaction of 20b (n=5) with the aniline keyintermediate 4a in the presence of pyridine furnished the coupling product 10a in 35% yield after puri®cation by column-chromatography (Scheme 1). The lower homologue 9a could not be obtained by similarly treating 4a with the valeric derivative 20a (n=4); in the presence of pyridine, the acid chloride 20a cyclized intramolecularly very rapidly (21, Scheme 2). Thus, in our hands, the peptidomimetic 15a (after deprotection of 9a) was not accessible. Treatment of 10a with tri¯uoroacetic acid produced the fully deprotected guanidyl derivative 16a. N-Deprotection of the aminocaproic derivative 6a and (iso)nipecotic derivatives 7a and 8a by hydrogenolysis, followed by treatment with tri¯uoroacetic acid to cleave the tertio-butyl ester, gave the unprotected compounds 12a, 13a and 14a, respectively (Scheme 1).
All the compounds 6±8, 10, 12±14, and 16 were fully characterized by the usual spectroscopic methods (see Experimental). The typical features in the 1 H NMR spectra of the tested compounds (unprotected derivatives in D 2 O) are as follows: (a) the three aromatic protons of the tyrosine backbone give respectively a ®ne doublet at 7.3±7.5 d (J $ 2 Hz), a doublet of doublet at 7.1±7.2 d (J $ 2 Hz and 8.7 Hz) and a doublet at 7.0±7.1 d (J $ 8.7 Hz); (b) the proton of the tyrosine a-CH group is a doublet of doublet at 4.6±4.8 d (J $ 5 and 9.5 Hz); (c) the protons of the tyrosine b-CH 2 group appear to be non-equivalent, giving a ABX pattern centred at 2.95±3.00 d and 3.25±3.30 d (JAB $ 14 Hz). In the 13 C NMR spectra (D 2 O), (a) the carbon atom of the CF 3 XPS tag is visible at 118 ppm (Q); (b) the three substituted carbon atoms of the tyrosine aromatic ring give lines at 153 ppm, 131 ppm and 127 ppm, corresponding to carbons linked to oxygen, nitrogen and carbon respectively; (c) the a and b carbons of the aliphatic tyrosine chain appear at 57 ppm and 38 ppm, respectively.
In another set of experiments, we considered the metatri¯uoromethyl-benzenesulfonyl group (XPS tag) for masking the a-amino function of the tyrosine template. Due to the high acidity of the sulfonamide proton, the presence of this function is not compatible with the phenol ring etheri®cation under the Williamson conditions. Accordingly, the sulfonylation of the a-amino function was performed after the tyrosine O-alkylation step. Thus, compound 3a (see Scheme 1) was submitted to basic hydrolysis to furnish the free amine 22 which was directly treated with meta-tri¯uoromethyl-benzenesulfonyl chloride and triethylamine; the sulfonamide 23 was puri®ed by¯ash-chromatography with medium yields (Scheme 3). Reduction of the aromatic nitro function by hydrogenation over platinium oxide gave the aniline key-intermediate 24. This aniline was coupled with N-(Cbz)-6-aminocaproyl chloride and with (N,N H -diterbutoxycarbonyl)-6-guanidino-caproyl chloride 20b as previously described; the corresponding anilides 25 and 26 were obtained in 48% and 24% yield after¯ash-chromatography. The ®nal deprotections were realized by hydrogenolysis followed by treatment with tri¯uoroacetic acid to give 27, and by treatment with tri¯uoroacetic acid to give 28 (Scheme 3). The NMR characteristics of compounds 25±28 are similar to those of the previous series bearing the tri¯uoro-acetamide group (see Experimental): the proton of the a-CH group gives a doublet of doublet at 4 d; the carbon of the CF 3 XPS tag is visible at 124 ppm (Q).
At last, we prepared a peptidomimetic fully equipped for the anchorage onto polymer substrates. Reduction of the aromatic nitro function of compound 3b (bearing the N-protected aminopropyl arm) by catalytic hydrogenation over platinium oxide gave the keyintermediate aniline 4b (Scheme 1). Coupling with the N-protected 6-guanidino-caproyl chloride 20b in the presence of pyridine furnished the anilide 10b in 51% yield after¯ash-chromatography. Complete deprotection of the ester, guanidino and amino functions was realized, as usual, by treatment with tri¯uoroacetic acid at room temperature; compound 16b was quantitatively recovered (Scheme 1). In the 1 H NMR spectrum, the three methylene protons of the anchorage-arm give multiplets at 2.13 d, 3.16 d and 4.16 d; the corresponding 13 C NMR lines are found at 28.9 ppm, 39.6 ppm and 68.5 ppm.
Biological evaluation (in solution)
The in vitro activity of the compounds listed in Table 1 was assayed in a standard test of platelet aggregation inhibition. 52 Human platelet rich plasma (PRP) was freshly prepared and platelet aggregation was measured by recording the velocity of light transmission change with an aggregometer. Serial dilutions of the inhibitors were added, and aggregation was induced by addition of adenosine diphosphate (ADP). Inhibition of platelet aggregation was determined by comparison of light transmittance values for the control (absence of inhibitor) and the samples. The IC 50 was determined as the concentration necessary to inhibit the change in light transmittance by 50%. We used the tetrapeptide RGDS (Arg-Gly-Asp-Ser) as active reference compound: it inhibits ADP-mediated platelet aggregation with a IC 50 value of about 100 mM.
We found that the 6-guanidino-(entries 1±3) and the 6-aminocaproic derivatives (entry 5) are inhibitors, while (Fig. 3) . 55 ,56 The references and compound 16a (Fig. 4) were fully optimized at the approximate quantum chemistry level AM1; the molecules were studied as isolated neutral entities, and not as zwitterionic forms, in order to avoid internal self-folded conformations.
As previously pointed out in the literature, 27 ,41 the overall length of c[RGDfV] is shorter comparatively to the a IIb b 3 ligands, such as DMP 728. Indeed, the structure is stabilized by two hydrogen-bonds between the C=OF F FN-H group of Gly and the adjacent amide bonds (distances of 2.216 A Ê and 2.568 A Ê , respectively) ( Fig. 3) . With its¯exible side-chains, the potential ligand 16a displays terminal functions that can be fairly ®tted onto the corresponding carboxyl-and guanidyl groups of both references (Figs 5 and 6).
Surface chemistry
Poly(ethylene terephthalate) (PET) is a synthetic aromatic polyester widely used as a biomaterial for making non-resorbable sutures, or performing prosthetic replacements in orthopedic surgery (tendons, ligaments, facial implants). Actually, the most successful medical applications of PET are in the area of cardiovascular surgery, including prosthetic heart valves and vascular grafts of large to medium diameter (Dacron).
1,2 Membranes made from PET ®lms are also appropriate substrates for cultivating mammalian cells. 4, 6 In our laboratory, we use microporous membranes obtained by a track-etching process which allows the preparation of capillary-pore' membranes 57 with very uniform, nearly perfectly round cylindrical pores. Such membranes are made from homogeneous 10±20 mm thick polymer ®lm precursors in two steps, consisting of bombardment with heavy ions (Ar +9 ) accelerated in a cyclotron, followed by immersion into an appropriate solution of reagents which preferentially etches the tracks, leading to the creation of pores. 58 The etching treatment of the PET creates functionalities (chain-endings) on the membrane open surface that could be used for immobilizing molecules of interest.
The surface displayed functions of PET membranes are carboxyl-and hydroxyl end-groups (Scheme 4). We have already demonstrated that the amount of carboxyl groups could be signi®cantly increased by a surface oxidative treatment (KMnO 4 in 1.2 N H 2 SO 4 ) which transforms native hydroxyl chain-ends into new carboxyl endings 7, 9 ; the resulting membrane was called PET-CO 2 H (Scheme 4).
The surface reactivity of the PET-CO 2 H membrane was assayed by the covalent coupling of 3 H-lysine followed by liquid scintillation counting (LSC) of the sample associated radioactivity. 7, 9 For that purpose, the labeling reaction was conducted under mild conditions (water solution, near the physiological pH, room temperature) mimicking at best the conditions to be encountered in the covalent coupling of the peptidomimetic molecule 16b. Thus, the PET membrane was activated by treatment with water soluble carbodiimide (0.1% WSC, 1 h, 20 C, pH 3.5) and then incubated with The RGD peptidomimetic 16b was similarly coupled to the PET-CO 2 H membrane activated by the pre-treatment with WSC (Scheme 4). A blank sample was prepared by immersing a non-activated PET-CO 2 H membrane into the solution of 16b in phosphate buer (0.062%, or $ 10 À3 M). The X-ray photoelectron spectroscopy (XPS) of the blank sample did not show the presence of¯uorine atoms on the surface (thus, no detectable adsorption). However, the activated membrane ®xed (most probably by covalent grafting) the RGD peptidomimetic as revealed by the presence of 0.24% of¯uorine atoms (XPS analysis) in the atomic composition of the sample surface (sampling depth of about 50 A Ê ). From the experimental F/C Â 100 atomic ratio of 0.339, we calculated (see Experimental) that about 1.1% of the surface monomer units have ®xed the biological signal. This value is in good agreement with the theoretical value based on the surface radiolabeling assay (1.2%). According to Massia and Hubbell, 59 ,60 a surface concentration of about 10 fmol/cm 2 of grafted natural peptides is large enough to improve the celladhesive properties of a biomaterial. Thus our PET substrate, displaying about 1% of synthetic`RGD-like' signals (i.e. about 30 pmol/cm 2 ) should be a good candidate to promote the adhesion of anchorage-dependent cells.
Conclusion
Several RGD peptidomimetics have been constructed from the ortho-amino-tyrosine template. The synthetic strategy allowed to equip the structures with an anchoragearm and a¯uorine tag, as required for the surface immoblilization on polymer substrates, and the subsequent quanti®cation of the amount of ®xed biological signals by X-ray photoelectron spectroscopy.
The most¯exible molecule 16 has been selected for coupling on the poly(ethylene terephthalate) membrane currently used as cell culture support. In solution, 16a,b exhibited moderate activities, in the platelet aggregation test, that range the compounds at the level of the tetrapeptide RGDS; the presence of an anchorage-arm did not perturb the biological response. The structure 16a could be fairly ®tted with two cyclic RGD peptides which are representative ligands of the ®brogen-and vitronectin receptors, respectively.
Using the wet-chemistry technique, we enriched the PET membrane surface with carboxyl functions. Their activation with WSC allowed to ®x the peptidomimetic 16b in good yield, as controlled by XPS: almost all the reactive CO 2 H chain-endings assayed by radiolabeling and LSC have quenched the biological signal.
To our knowledge, the present work is the ®rst report dealing with the covalent coupling of RGD peptidomimetics on the surface of PET membrane. The performances of such a modi®ed support are currently examined in our laboratory by culturing dierent mammalian cell lines.
Experimental Synthesis
The reagents (analytical grade) were purchased from Acros, Aldrich, or Fluka. The solvents were distilled, after drying as follows: acetonitrile, dichloromethane, dimethoxyethane, triethylamine and pyridine, over calcium hydride; tetrahydrofurane, over sodium; acetone, over drierite.
The thin-layer chromatographies were carried out on silica gel 60 plates F254 (Merck, 0.2 mm thick); visualization was eected with UV light, iodine vapor, a spray of ninhydrin in ethanol or a spray of potassium permanganate (3 g) and potassium carbonate (20 g) in aqueous acetic acid (1%, 300 mL). The columnchromatographies (under normal pressure) were carried out with Merck silica gel 60 of 70±230 mesh ASTM, and the¯ash-chromatographies, with Merck silica gel 60 of 230±400 mesh ASTM. The MPLC puri®cations were realized on a Prochrom equipment, with silica gel of 400 mesh ASTM, under a pressure of 40 bar and a¯ow of 160 mL/min.
The melting points were determined with an Electrothermal microscope and are uncorrected. The rotations ( 0.1 ) were determined on a Perkin±Elmer 241 MC polarimeter. The IR spectra were taken with a Perkin± Elmer 600 instrument or with a Bio-Rad FTS 135 instrument, and calibrated with polystyrene (1601 cm À1 ). The 1 H and 13 C NMR spectra were recorded on Varian Gemini 300 (at 300 MHz for proton and 75 MHz for carbon), or Bruker AM-500 spectrometers (at 500 MHz for proton and 125 MHz for carbon); the chemical shifts are reported in ppm (d) down®eld from tetramethylsilane (internal standard), or sodium 2,2-dimethyl-2-silapentane-5-sulfonate (DSS) for the spectra recorded in D 2 O. The atom numbering used for the description of the spectra is shown in the Figure 7 ; the attributions were established by selective decoupling experiments. The mass spectra were obtained on a Finnigan-MAT TSQ-70 instrument at 70 eV (electronic impact (EI) mode), or with a Xenon ION TECH 8 KV (fast atom bombardment (FAB) mode). The microanalyses were performed at the Christopher Ingold Laboratories of the University College, London. The HRMS were performed at the University of LieÁ ge (Belgium) on a VG-AutoSpec-Q equipment (Fisons Instruments, Manchester).
N-(Tri¯uoroacetyl)-ortho-nitro-l-tyrosine terbutylester (2). l-Tyrosine t-butylester 1 (478 mg, 2.013 mmol) was Figure 7 . Atoms numbering used in the NMR spectra description. dissolved, at 0 C, in tri¯uoroacetic anhydride (1.5 mL, 2.23 g, 10.6 mmol, 5.27 equiv). After 30 min of stirring at room temperature, the mixture was concentrated under vacuum. The residue was dissolved in acetic acid (15 mL) and treated with concentrated nitric acid (115 mL, 2.4 mmol, 1.2 equiv) diluted in acetic acid (15 mL); the solution of HNO 3 was added dropwise, and the mixture was maintained at 10±14
C during the addition. After 75 min of reaction (TLC control), the crude mixture was poured onto ice (400 g). The yellow precipitate was ®ltered o. The aqueous phase was extracted with ethyl acetate (4Â150 mL). The organic phases were dried over MgSO 4 
To a solution of 4a (514 mg, 1.419 mmol) in CH 2 Cl 2 (10 mL) were added, successively, the acid chloride 20b (612 mg, 1.561 mmol, 1.1 equiv) and pyridine (0.130 mL, 127 mg, 1.607 mmol, 1.13 equiv) in CH 2 Cl 2 (10 mL). The mixture was stirred during 20 h at room temperature. Washing with 1.5 N HCl (2Â20 mL), 10% NaHCO 3 (2Â20 mL), and water (2Â20 mL), drying over MgSO 4 and concentration gave crude 10a which was puri®ed by column-chromatography on silica gel (hexane:ether 
To a solution of 4a (874 mg, 1.728 mmol) and pyridine (411 mg, 5.192 mmol, 3 equiv) in CH 2 Cl 2 (10 mL), was added the acid chloride 20b (742 mg, 1.893 mmol, 1.09 equiv) in CH 2 Cl 2 (10 mL). The mixture was stirred for 15 h at room temperature, under molecular sieves (4 A Ê ). Washing with 1.5 N HCl (2Â20 mL), 10% NaHCO 3 (2Â20 mL), and brine (2Â20 mL), drying over MgSO 4 and concentration gave crude 10b which was¯ash-chromatographed (silica gel, hexane:isopropanol, 9:1) to furnish 750 mg of 10b (yield: 51%): R f =0. C (TLC control), then washed with 1 N HCl (3Â10 mL), 10% NaHCO 3 (3Â10 mL), and brine (3Â10 mL). Drying (MgSO 4 ), concentration and¯ash-chromatography (silica gel, hexane-isopropanol, 10:1) gave 380 mg of 7a (yield: 56%): R f =0.1; mp 62.3±63. 
N-(Tri¯uoroacetyl)-O-methyl-ortho-[6-(benzyloxycarbonyl)-amino-caproyl]-amino-L-tyrosine terbutylester (6a). N-
N-(Tri¯uoroacetyl)-O-methyl-ortho-[N-(benzyloxycarbon- yl)-nipecotyl]-amino-L-tyrosine terbutylester (8a). N- (Benzyloxycarbonyl)-
N-(Tri¯uoroacetyl)-O-methyl-ortho-(6-guanidino-caproyl)-amino-(L)-tyrosine (16a).
The Boc-protected precursor 10a (76.5 mg, 0.106 mmol) was dissolved in tri¯uoro-acetic acid (1.7 mL) and left for 2.5 h at 20 C. After evaporation under vacuum, the residue was dissolved in water and washed with chloroform. The aqueous phase was freeze-dried to give 58 mg of 16a (yield: 86%): mp 95.5±96. 
A solution of 6a (55 mg, 0.09 mmol) in EtOAc (5 mL)) was placed in a Parr¯ask and hydrogenated (pH 2 =40 psi) in the presence of Palladium (10% on C, 2 mg, 0.21 equiv). The mixture was vigorously shaked during 72 h (fresh catalyst was added three times). After ®ltration and concentration, the residue was dissolved in CHCl 3 , dried over MgSO 4 and concentrated under vacuum. The residue was dissolved in CF 3 CO 2 H (2 mL) and left for 2.5 h at 20 C. After evaporation, the residue was dissolved in water and extracted with CHCl 3 . The aqueous phase was freeze-dried to give 40 mg of 12a (yield: 100%): IR (CD 3 OD) n 3419, 2947, 2361, 1683, 1541, 1490, 1207, 1143, 1029 cm O-Methyl-ortho-nitro-L-tyrosine terbutylester (22) . To a solution of 3a (2.27 g, 5.785 mmol) in MeOH:H 2 O (1:1, 100 mL), was added K 2 CO 3 (4.207 g, 30.14 mmol). The mixture was stirred during 17 h at 20 C, then concentrated under vacuum. Toluene was added and distilled. The residue was dissolved in CH 2 Cl 2 and washed with water (3Â). The organic phase was dried (MgSO 4 ), and concentrated under vacuum to give the crude amine 22 (1.504 g, 88% yield): R f (SiO 2 ; CH 2 Cl 2 :EtOAc, 9:1)=0.1; IR (CHCl 3 ) n 3383, 2977, 2934, 1727, 1623,  1531, 1506, 1457, 1358, 1289, 1260, 1154 N-(meta-Tri¯uoromethyl-benzenesulfonyl)-O-methyl-ortho-(6-amino-caproyl)-amino-l-tyrosine (27) Benzyl 6-amino-caproate para-toluene sulfonate (18b). A mixture of 6-aminocaproic acid (5 g, 38.11 mmol), benzyl alcohol (250 mL) and para-toluene sulfonic acid (8.38 g, 42.3 mmol, 1.1 equiv) in benzene (500 mL) was heated at 100 C for 3 h (azeotropic distillation with a Dean±Stark equipment). The solution was cooled to 20 C under argon atmosphere. After addition of ether (500 mL), the product was allowed to crystallize at À30 C, during 3 days. (20 mL) was re¯uxed (50 C) during 1.5 h, then concentrated under vacuum. The excess of SOCl 2 was removed by azeotropic distillation with toluene (3Â) and CHCl 3 (3Â). The acid chloride 20b was dried under high vacuum (617 mg, 98% yield) and used without puri®cation.
Biological evaluation (in solution)
The purity of the pepdidomimetics was controlled by HPLC before use, with the following conditions: column: Nucleosil C18, 5 m, 25 cm; temperature: 25 C; eluent: gradient from 20% CH 3 CN+0.015% TFAÀ80% H 2 O+0.015% TFA to 80% CH 3 CN+0.015% TFA À20% H 2 O+0.015%;¯ow rate: 1 mL/min; equipment: Beckman, System Gold, 126 P Solvent module, 168 Detector (Analis, Belgium). The retention times (area) were: 16b: t=5.43 min (98.8%); 16a: t=7.53 min (96.9%); 12a: t=6.88 min (100%); 13a: t=11.53 min (94.1%); 27: t=8.67 min (98.5%).
The phosphate buered saline (PBS) solution (pH 7.3) was prepared from NaCl (4 g), KCl (0.1 g), KH 2 PO 4 (0.1 g) and Na 2 HPO 4 , 2H 2 O (0.71 g) dissolved in water (HPLC grade, 500 mL). The stock solutions of peptidomimetics contained 1 to 5 mg of product per milliliter of PBS buer; if needed, 0.5% DMSO could be added for complete dissolution. The tested concentrations were within 10 À6 to 10 À1 M.
Blood was drawn from the antecubital vein of healthy adult volunteers, who denied taking any medication for the previous 15 days, into a plastic syringe containing one part of 3.8% trisodium citrate to nine parts of blood. Platelet rich plasma (PRP) was prepared by centrifuging the blood at 1500 g for 10 min at room temperature. The PRP was drawn o and the remaining blood was centrifuged at 6000 g for 20 min at room temperature to make platelet poor plasma (PPP). The PRP was adjusted with PPP to a count of 3Â10 5 platelets/mL; platelet count was measured with a Coulter counter. 400 mL of the PRP preparation and 50 mL of the solution of peptidomimetic to be tested, or saline, were preincubated for 2 min at 37 C in an aggregometer; 50 mL of 0.047 mM ADP were added, and the aggregation was monitored during 4 min. Results were calculated as follows: [observed % aggregation (antagonist)] divided by [maximum % aggregation (control)] equals the % of control. The % inhibition=100À% of control. Concentration±response curves were constructed and the IC 50 were determined as the concentration of antagonist required to produce 50% inhibition of the response to the agonist. At least two determinations were made for each compound and the IC 50 calculated by ®tting to a four parameter equation (average standard error of 30%).
Modelisation
All the degrees of freedom describing the molecular geometry have been fully optimized at the approximate quantum chemistry level AM1, 61 using the minimization procedures available in Gaussian suite of programs. 62 In 
